Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 12:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Cardiac Event Clear all
Completed No phase listed Observational Results available

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

NCT01088503
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
ADP receptor inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
185
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Not applicable Interventional

Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome

NCT01500902
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
EndoPAT testing (non invasive device), WatchPAT testing (non-invasive device)
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Jun 11, 2026, 12:10 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

NCT06602453
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
GDC-8264, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Stanford, California • Tampa, Florida • Lutherville, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
18,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Jun 11, 2026, 12:10 AM EDT
Completed No phase listed Observational

Impact of OSA on Outcomes in Acute Coronary Syndrome

NCT03793582
View directory record Official record
Conditions
OSA, ACS - Acute Coronary Syndrome, Major Adverse Cardiac Events
Interventions
ApneaLink Type III portable sleep study
Diagnostic Test
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Jun 11, 2026, 12:10 AM EDT
Terminated No phase listed Observational

The Ischemia Modified Albumin In Diagnosing Ischemic New Events

NCT00355992
View directory record Official record
Conditions
Heart Disease, Ischemic, Ischemia, Myocardial, Ischemic Heart Disease, Unstable Angina
Interventions
Not listed
Lead sponsor
Inverness Medical Innovations
Industry
Eligibility
21 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2009 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jun 11, 2026, 12:10 AM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

NCT05754957
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Milvexian, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
14,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
162
States / cities
Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 11, 2026, 12:10 AM EDT
Suspended Phase 3 Interventional

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

NCT00353067
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
veliflapon (DG-031)
Drug
Lead sponsor
deCODE genetics
Industry
Eligibility
35 Years and older
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 2 Interventional Results available

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

NCT00356135
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 2 Interventional Results available

Study Effect of VIA-2291 on Vascular Inflammation

NCT00358826
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
VIA-2291, Placebo
Drug
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Melbourne, Florida • Minneapolis, Minnesota • Tupelo, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

NCT01042769
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Aleglitazar, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
7,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
221
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562
View directory record Official record
Conditions
Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions
Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
21,379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
250
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Jun 11, 2026, 12:10 AM EDT
Completed No phase listed Observational

PARA-HEART Pilot Implementation

NCT02709135
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 11, 2026, 12:10 AM EDT
Not listed No phase listed Observational

Biomarkers of Acute Stroke in Clinic

NCT03897478
View directory record Official record
Conditions
Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions
ISCDX blood test
Diagnostic Test
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Jun 11, 2026, 12:10 AM EDT
Completed No phase listed Observational

Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury

NCT04095143
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload, Ultrasonography
Interventions
Portal vein flow, Intra-renal flow, Hepatic vein flow, Pulmonary B-lines, Dimensions of the inferior vena cava, Left ventricular function, Right ventricular function
Diagnostic Test
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jun 11, 2026, 12:10 AM EDT
Not yet recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 11, 2026, 12:10 AM EDT
Active, not recruiting Not applicable Interventional

Post Acute Cardiac Event Smoking (PACES) Study

NCT03413423
View directory record Official record
Conditions
Acute Coronary Syndrome, Tobacco Use
Interventions
BAT-CS, Smoking Cessation and Health & Wellness
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jun 11, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

NCT00335452
View directory record Official record
Conditions
Acute Coronary Disease, Angina Unstable
Interventions
Clopidogrel, acetylsalicyclic acid (ASA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
25,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Jun 11, 2026, 12:10 AM EDT